Skip to main content
SpringerLink
Log in
Book cover

Immunohistochemistry in Tumor Diagnostics pp 83–93Cite as

Markers and Immunoprofile of Tumors of Female Reproductive Organs

  • Chapter
  • First Online:

  • 2769 Accesses

Abstract

Please check the hierarchy of the section headings and correct if necessary.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Parenti R, Perris R, Vecchio GM, et al. Immunohistochemical expression of Wilms’ tumor protein (WT1) in developing human epithelial and mesenchymal tissues. Acta Histochem. 2013;115(1):70–5.

    Article  CAS  PubMed  Google Scholar 

  2. Egashira N, Takekoshi S, Takei M, et al. Expression of FOXL2 in human normal pituitaries and pituitary adenomas. Mod Pathol. 2011 Jun;24(6):765–73.

    Article  CAS  PubMed  Google Scholar 

  3. Novak M, Lester J, Karst AM, et al. Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Gynecol Oncol. 2015;139(1):104–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. He M, Aisner S, Benevenia J, et al. p16 immunohistochemistry as an alternative marker to distinguish atypical lipomatous tumor from deep-seated lipoma. Appl Immunohistochem Mol Morphol. 2009;17(1):51–6.

    Article  CAS  PubMed  Google Scholar 

  5. Thway K, Flora R, Shah C, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012;36(3):462–9.

    Article  PubMed  Google Scholar 

  6. Yu D-D, Guo S-W, Jing Y-Y, et al. A review on hepatocyte nuclear factor-1 beta and tumor. Cell Biosci. 2015;5:58.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1 beta (HNF-1beta) in clear cell tumors and endometriosis. Mod Pathol. 2006;19(1):83–9.

    Google Scholar 

  8. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:580–7.

    Article  CAS  PubMed  Google Scholar 

  9. Lotan TL, Gumuskaya B, Rahimi H, et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2013;26(4):587–603.

    Article  CAS  PubMed  Google Scholar 

  10. Garg K, Broaddus RR, Soslow RA, et al. Pathological scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol. 2012;31(1):48–56.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zhang HY, Liang F, Jia Z-L, et al. PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett. 2013;6:161–8.

    PubMed  PubMed Central  Google Scholar 

  12. Wei J-J, Paintal A, Keh P. Histologic and immunohistochemical analyses of endometrial carcinoma: experiences from endometrial biopsies in 358 consultation cases. Arch Pathol Lab Med. 2013;137:1574–83.

    Article  PubMed  Google Scholar 

  13. Kelly TW, Border Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol. 2004;12(4):338–41.

    Article  Google Scholar 

  14. Kwasniewska A, Postawski K, Gozdzicka-Jozefiak A, et al. Estrogen and progesterone receptor expression in HPV positive and HPV negative cervical carcinomas. Oncol Rep. 2011;26(1):153–60.

    PubMed  Google Scholar 

  15. Kommoss S, Anglesio MS, Mackenzie R, et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol. 2013;26:860–7.

    Article  CAS  PubMed  Google Scholar 

  16. Kommos S, Anglesio MS, Mackenzie R, et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol. 2013;26:860–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Carl-Thiem-Klinikum, Institut für Pathologie, Cottbus, Germany

    Muin S. A. Tuffaha

  2. Vivantes Klinikum Neukölln, Institut für Pathologie, Berlin, Germany

    Hans Guski

  3. Universität Bonn, UKB, Institut für Pathologie, Bonn, Germany

    Glen Kristiansen

Authors
  1. Muin S. A. Tuffaha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Guski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glen Kristiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Tuffaha, M.S.A., Guski, H., Kristiansen, G. (2018). Markers and Immunoprofile of Tumors of Female Reproductive Organs. In: Immunohistochemistry in Tumor Diagnostics. Springer, Cham. https://doi.org/10.1007/978-3-319-53577-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53577-7_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53576-0

  • Online ISBN: 978-3-319-53577-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation